NCTN Adolescent to Young Adult (AYA) Cancer Trials Portfolio (Open as of 5/17/2021)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

### Newly Diagnosed Disease

- **Soft Tissue Sarcoma**
  - ARST1431

- **Germ Cell Tumors**
  - AGCT1531
  - AGCT1532

- **Acute Lymphoblastic Leukemia (ALL)**
  - A041501

- **Classical Hodgkin Lymphoma**
  - S1826

- **TFE/Translocation Renal Cell Carcinoma (tRCC)**
  - AREN1721

### Recurrent Disease

- **Germ Cell Tumors**
  - A031102 (TIGER)

- **Classical Hodgkin Lymphoma**
  - E4412

- **Acute Lymphoblastic Leukemia (ALL)**
  - AALL1821

### Legend by Disease Types

- Green = Soft Tissue Sarcoma
- Yellow = Germ Cell Tumors
- Blue = ALL
- Lime green = Hodgkin Lymphoma
- Purple = tRCC

### Cross-disease trials

- EAY131 (MATCH)
- S1609 (DART)*
- NCICOVID (NCCAPS)

*: COG not participating
### NCTN Adolescent to Young Adult (AYA) Cancer Trials (Open as of 5/17/2021)

<table>
<thead>
<tr>
<th>Protocol Number</th>
<th>Phase</th>
<th>Protocol Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>A031102</td>
<td>III</td>
<td>A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors</td>
</tr>
<tr>
<td>A041501</td>
<td>III</td>
<td>A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL</td>
</tr>
<tr>
<td>AALL1821</td>
<td>II</td>
<td>A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged &gt;/= 1 to &lt; 31 Years Old with First Relapse</td>
</tr>
<tr>
<td>AGCT1531</td>
<td>III</td>
<td>A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors</td>
</tr>
<tr>
<td>AGCT1532</td>
<td>III</td>
<td>A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors</td>
</tr>
<tr>
<td>AREN1721</td>
<td>II</td>
<td>A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups</td>
</tr>
<tr>
<td>ARST1431</td>
<td>III</td>
<td>A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)</td>
</tr>
<tr>
<td>E4412</td>
<td>I/II</td>
<td>A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma</td>
</tr>
<tr>
<td>NCICOV1D</td>
<td>Other</td>
<td>NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study</td>
</tr>
<tr>
<td>S1826</td>
<td>III</td>
<td>A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age &gt;/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma</td>
</tr>
<tr>
<td>EAY131</td>
<td>II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>S1609*</td>
<td>II</td>
<td>DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors</td>
</tr>
</tbody>
</table>

*: COG not participating